Skip to main content
DIACEUTICS PLC logo

DIACEUTICS PLC — Investor Relations & Filings

Ticker · DXRX ISIN · GB00BJQTGV64 LEI · 213800VEWQBB39ZB8J81 IL Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 278 across all filing types
Latest filing 2022-10-05 Director's Dealing
Country GB United Kingdom
Listing IL DXRX

About DIACEUTICS PLC

https://www.diaceutics.com/

Diaceutics PLC is a data analytics and end-to-end services provider focused on the development and commercialization of precision medicine diagnostics. The company supports pharmaceutical and biotech clients by providing solutions to improve the diagnostic testing ecosystem, aiming to ensure patients receive the correct personalized treatment. Its primary offering is DXRX, The Diagnostic Network®, a diagnostic commercialization platform for precision medicine. DXRX facilitates collaboration among stakeholders, including laboratories and pharmaceutical companies, in a secure marketplace and provides access to real-world diagnostic testing data. This integrated platform is designed to streamline the launch and adoption of new precision medicines.

Recent filings

Filing Released Lang Actions
Purchase of Shares and PDMR Shareholding
Director's Dealing Classification · 99% confidence The document is an official announcement identified by the 'RNS Number' and the reference to 'RNS is approved by the Financial Conduct Authority'. The content explicitly details a 'Purchase of Shares' by a Director/Chair ('Deborah Davis, the Chair of Diaceutics') and includes a formal notification table structured under 'Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014'. This type of filing, reporting personal share transactions by company directors and executives, directly corresponds to the definition of Director's Dealing (DIRS). The document length is short (4759 chars), but the content is the primary disclosure itself, not an announcement of a separate report, thus ruling out RPA/RNS as the primary classification.
2022-10-05 English
Half-year Report
Interim / Quarterly Report Classification · 100% confidence The document is a 'Half Year Report' for Diaceutics PLC for the period ended 30 June 2022. It contains comprehensive financial highlights, operational highlights, a Chief Executive Review, and detailed business performance analysis. It is not an announcement of a report (RPA) because it contains the full text of the financial results and analysis. It fits the definition of an Interim/Quarterly Report (IR) as it covers a period shorter than a full fiscal year and includes substantive financial data. H1 2022
2022-09-27 English
PDMR Shareholding/Share Incentive Plan
Director's Dealing Classification · 99% confidence The document is titled 'PDMR Shareholding/Share Incentive Plan' and explicitly states it is a 'Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014'. It details share purchases and matched awards for several Persons Discharging Managerial Responsibilities (PDMRs) like the CFO and CCO. This type of filing, reporting insider transactions by directors/executives, directly corresponds to the definition of Director's Dealing (DIRS). Although it is distributed via RNS, the specific content mandates the DIRS classification over the general RNS fallback.
2022-09-12 English
Notice of Results and Presentations
Report Publication Announcement Classification · 99% confidence The document is a short announcement (3726 characters) released via RNS (London Stock Exchange news service). The title is "Notice of Results and Presentations". The text explicitly states that the company "expects to announce its unaudited interim results for the six months ended 30 June 2022 on Tuesday, 27 September 2022" and details subsequent analyst and investor presentations. Because this document is an announcement *about* the upcoming release of results and presentations, rather than the results themselves (Interim Report/IR) or the presentation slides (IP), it fits the definition of a Report Publication Announcement (RPA). It announces the publication schedule for the results and associated events.
2022-09-08 English
PDMR Shareholding/Share Incentive Plan
Director's Dealing Classification · 99% confidence The document is an RNS (Regulatory News Service) announcement from Diaceutics PLC, dated August 8, 2022. The core content explicitly details share transactions by Persons Discharging Managerial Responsibilities (PDMRs) under the Share Incentive Plan (SIP), referencing Article 19(1) of Regulation (EU) No. 596/2014. This type of filing, reporting personal share transactions by directors/executives, directly corresponds to the definition of Director's Dealing (DIRS). Although it is distributed via RNS, the specific content dictates the DIRS classification over the general RNS fallback.
2022-08-08 English
Trading Update and Notice of Results
Earnings Release Classification · 100% confidence The document is titled "Trading update for the six months ended 30 June 2022" and provides key unaudited financial highlights (revenue, order book, cash) for the first half (H1) of the year. It explicitly states that the Company "intends to report unaudited results for the six months ended 30 June 2022 on 27 September 2022." Since this document only provides a preliminary update and announces the future date of the full results, it functions as an Earnings Release (ER) or a precursor to the full Interim Report (IR). Given that it contains key financial metrics and is an announcement ahead of the formal filing, 'ER' (Earnings Release) is the most appropriate classification for this high-level summary of period performance. The document length is relatively short (4571 chars) and it is an announcement, but it contains substantive financial data, distinguishing it from a simple RPA. H1 2022
2022-07-26 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.